Skip to main content

BioFocus to Offer Activiomics' Proteomics Services

NEW YORK (GenomeWeb News) – BioFocus will offer its customers Activiomics' proteomics services for identifying novel biomarkers for diagnostics and targets for new drugs, the companies said today.

Under a strategic agreement, BioFocus will offer its customers Activiomics' Targeted In-depth QUAntification of cell Signaling, or TIQUAS, technology for proteomics studies in oncology, inflammation, and metabolic disease.

Financial and other terms of the deal were not disclosed.

TIQUAS uses mass spectrometry to detect and quantify phosphorylation sites from a cell or tissue extract, which can be used to discover which proteins and pathways are activated. Changes in phosphorylation status signal a change in protein activity.

Activiomics, headquartered in London, was founded in 2009 as a private spin-out from the Barts Cancer Institute.

“Proteomics analysis, in particular phosphoproteomics, is becoming ever more important in drug discovery programs. By partnering with Activiomics, BioFocus extends its offering of high-quality scientific expertise into this newly emerging area," Chris Newton, managing director at BioFocus and senior VP of Galapagos Services, said in a statement.

BioFocus, headquartered in the UK, is a Galapagos company.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.